Table 1: Baseline and clinical data.
|
|
Control (N=48) |
RIPC (N=49) |
|
Demographics and comorbidities |
|
|
|
Age (years) |
63.9±9.1 |
65.4±8.5 |
|
Sex (male) |
39 (81%) |
42 (86%) |
|
Arterial hypertension |
30 (62.5%) |
27 (55%) |
|
Preoperative medication |
|
|
|
β-blockers |
29 (60%) |
37 (75.5%) |
|
Digoxin |
0 |
3 |
|
ACE inhibitors/ARBs |
20 (42%) |
18 (37%) |
|
Eplerenone |
2 |
11 |
|
Spironolactone |
0 |
2 |
|
Echocardiography |
|
|
|
LVEF (%) |
44.2±10.6 |
47.86±11 |
|
Left atrial diameter (mm) |
38.6±3.7 |
39.7±5.8 |
|
Intraoperative data |
|
|
|
CABG x II |
3 (6.3%) |
5 (10.2%) |
|
CABG x III |
33 (68.7%) |
35 (71.5%) |
|
CABG x IV |
12 (25%) |
9 (18.3%) |
|
Valve replacement+CABG |
2 |
3 |
|
Aortic cross-clamp time (min) |
63.7±25 |
68.58±18.5* |
|
Total CPB time (min) |
98.1±28.1 |
102.4±28.4 |
ACE, angiotensin conveting enzyme; ARB, angiotensin receptor blocker; LVEF, left ventricular ejection fraction; CABG, coronary artery bypass grafting; II, III, IV indicate the number of grafts; CPB, cardio-pulmonary bypass. *P<0.05 (control vs RIPC).